Tumor Biomarkers in Gynecology
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1287
Special Issue Editors
Interests: gynecology; obstetrics; gynecology oncology; minimally invasive surgery; endocrinology; tumor biomarkers; human papilloma virus
Special Issues, Collections and Topics in MDPI journals
Interests: gynecology; gynecologic oncology; minimally invasive surgery; urogynecology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gynecological cancers are frequently found in the female population worldwide. Despite the efforts of scientists in implementing screening and early diagnosis programs, only in cervical cancer have we been able to identify an effective method of prevention.
In relation to ovarian cancer, the literature has analyzed well-known CA125 and HE4, which are historically reliable, but early-stage diagnosis requires the implementation of more precise biomarkers. Attempts are being made to introduce liquid biopsy for early detection to identify promising biomarkers among microRNAs.
Although used for endometrial cancer, the known protein CA-19.9 is imprecise and was surpassed by HE4, whose clinical utility may be limited by the lower sensitivity, but it is strongly related to the prognosis. The new frontier with higher specificity and sensitivity are proteomic biomarkers (i.e., YKL-40, DJ-1) and promising exonal biomarker miRNA (i.e., 21,27 and 223).
In breast cancer, CA15.3 is the best-known tumor marker, and it is well-associated with the tumor stage. New horizons are also being studied in this field, looking for new, more effective markers on peripheral blood for early diagnosis and risk stratification for the development of breast cancer, such as hypermethylation of cell-free DNA or circular RNAs on prognosis and treatment.
Dr. Corrado Terranova
Dr. Francesco Plotti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
